Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 17, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of specific share transactions and does not contain financial performance data.
Material Changes
No material changes to the company's financial position or operations are reported. The filing details specific share movements within the SmithKline Beecham Employee Benefit Trust ("the Trust") on January 12, 2006:
- Share Purchase: 662 Ordinary shares were purchased for participants in the GlaxoSmithKline Bonus Investment Plan at a price of GBP 14.52 per share. This followed the reinvestment of a cash dividend paid on January 5, 2006.
- Share Transfer: 11 Ordinary shares were transferred from the Trust to a participant in the GlaxoSmithKline Annual Investment Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the Trust is a discretionary fund for non-US employees and former employees, and that Director Mr. J. Heslop holds an interest in the fund shares in the same capacity as other eligible employees.
Investor Verification Checklist
- Verify the total number of shares held by the SmithKline Beecham Employee Benefit Trust to assess the scale of the reported transactions.
- Confirm the current share price relative to the GBP 14.52 transaction price reported for January 12, 2006.
- Review the full terms of the GlaxoSmithKline Bonus Investment Plan and Annual Investment Plan to understand the mechanics of the reinvestment and transfers.
- Check subsequent filings for any further changes in Director interests or Trust holdings.